Zimmer Biomet Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $8.5B+10.8% YoYTTM through 30 Jun 2026
Net Income $806.7M-10.7% YoYTTM through 30 Jun 2026
Free Cash Flow $1.5BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 61.6% |
| EBITDA Margin | 27.2% |
| Operating Margin | 13.3% |
| Net Margin | 9.5% |
Returns
5.5%ROE
3.1%ROA
4.1%ROIC
Balance Sheet Health
Debt / Equity0.59x
Current Ratio1.69x
Net Debt$6.9B
Cash & Equivalents$410M
Quality Metrics
Altman Z-Score2.45
Piotroski F-Score6 / 9
FCF Margin17.9%
Rule of 4018.9
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $8.2B
Diluted EPS$4.12TTMFY2025: $3.55
Dividend
$0.48Per share, FY20260.51%Yield-12.4%5-yr growth
Capital Allocation
Capex Intensity2.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Americas | $5.1B | +7.3% | |
| EMEA | $1.8B | +8.1% | |
| Asia Pacific | $1.3B | +5.5% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.